Trial Profile
Phase I, Multicenter, Open-label, Dose-escalating, Clinical and Pharmacokinetic Study of PM060184 Administered Intravenously to Patients With Advanced Solid Tumors
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 02 Dec 2018
Price :
$35
*
At a glance
- Drugs Plocabulin (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man
- Sponsors PharmaMar
- 09 Nov 2018 Results published in the Investigational New Drugs
- 18 Sep 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 14 Sep 2015 According to a PharmaMar media release, data from this study will be presented at the 18th ECCO - 40th ESMO European Cancer Congress (ECC 2015).